Cargando…

Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant

Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Sayami, Hirobe, Sachiko, Kawakita, Takuto, Saito, Mio, Quan, Ying-Shu, Kamiyama, Fumio, Ishii, Ken J., Nagao, Mizuho, Fujisawa, Takao, Tachibana, Masashi, Okada, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151019/
https://www.ncbi.nlm.nih.gov/pubmed/32183437
http://dx.doi.org/10.3390/pharmaceutics12030267
_version_ 1783521153243938816
author Ito, Sayami
Hirobe, Sachiko
Kawakita, Takuto
Saito, Mio
Quan, Ying-Shu
Kamiyama, Fumio
Ishii, Ken J.
Nagao, Mizuho
Fujisawa, Takao
Tachibana, Masashi
Okada, Naoki
author_facet Ito, Sayami
Hirobe, Sachiko
Kawakita, Takuto
Saito, Mio
Quan, Ying-Shu
Kamiyama, Fumio
Ishii, Ken J.
Nagao, Mizuho
Fujisawa, Takao
Tachibana, Masashi
Okada, Naoki
author_sort Ito, Sayami
collection PubMed
description Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin.
format Online
Article
Text
id pubmed-7151019
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71510192020-04-20 Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant Ito, Sayami Hirobe, Sachiko Kawakita, Takuto Saito, Mio Quan, Ying-Shu Kamiyama, Fumio Ishii, Ken J. Nagao, Mizuho Fujisawa, Takao Tachibana, Masashi Okada, Naoki Pharmaceutics Article Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin. MDPI 2020-03-15 /pmc/articles/PMC7151019/ /pubmed/32183437 http://dx.doi.org/10.3390/pharmaceutics12030267 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ito, Sayami
Hirobe, Sachiko
Kawakita, Takuto
Saito, Mio
Quan, Ying-Shu
Kamiyama, Fumio
Ishii, Ken J.
Nagao, Mizuho
Fujisawa, Takao
Tachibana, Masashi
Okada, Naoki
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title_full Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title_fullStr Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title_full_unstemmed Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title_short Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
title_sort characteristic of k3 (cpg-odn) as a transcutaneous vaccine formulation adjuvant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151019/
https://www.ncbi.nlm.nih.gov/pubmed/32183437
http://dx.doi.org/10.3390/pharmaceutics12030267
work_keys_str_mv AT itosayami characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT hirobesachiko characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT kawakitatakuto characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT saitomio characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT quanyingshu characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT kamiyamafumio characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT ishiikenj characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT nagaomizuho characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT fujisawatakao characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT tachibanamasashi characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant
AT okadanaoki characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant